Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 115,935

Document Document Title
WO/2023/247736A1
The invention relates to alpha1-antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof and/or a corresponding nucleic acid sequence for use in the treatment of diseases or disorders of the nervous system such as chron...  
WO/2023/248226A1
Disclosed are cannabis compositions and methods of using same for treating anxiety of a subject in need thereof, the cannabis composition characterized by comprising a predetermined minimal amount/concentration of CBCA.  
WO/2023/247389A1
Described herein are novel crystalline forms of 6-((5-methyl-3-(6-methylpyridin-3-yl)isoxazol-4- yl)methoxy)-N-(tetrahydropyran-4-yl)pyridazine-3-carboxamide , as well as pharmaceutical compositions comprising the same, processes for mak...  
WO/2023/242281A1
The invention relates to a compound derived from sterols of formula (I) for the use thereof in the prevention, improvement and/or treatment of a disease associated with a mitochondrial deficit chosen from the group made up of autism, spi...  
WO/2023/243971A1
The present invention relates to a pharmaceutical composition for preventing or treating demyelinating disease, comprising as an active ingredient a kinase inhibitor that has been confirmed to promote motility recovery and oligodendrocyt...  
WO/2023/242442A1
A method of in vivo neuron maturation/differentiation AND/OR a method in vivo neuron maturation/differentiation and/or vagus nerve modulation by administering a therapeutic amount of a composition comprising IGF-1, for example in a compl...  
WO/2023/244542A1
Described herein are detecting methods for conformational disease, aging and proteinopathies, by measuring the presence of b-isox-precipitates and the levels of b-isox-captured proteins in biofluids of healthy individuals and patients. R...  
WO/2023/244611A1
This disclosure relates to methods of treating, preventing, or reversing inflammation-associated central nervous system (CNS) disorders or conditions comprising administering an effective amount of a Janus kinases (JAK) inhibitor such as...  
WO/2023/240379A1
Provided in the present invention are an imidazolinone derivative and the use thereof. The imidazolinone derivative is a compound having a structure as shown in the following formula (I) or (II) or a pharmaceutically acceptable salt, ste...  
WO/2023/242696A1
Provided is at least one terpene for use in modulation of a physiological function via modulation of activation of a Transient Receptor Potential (TRP) channel receptor, wherein the TRP is a member of subfamily A (TRPA) and the terpene i...  
WO/2023/241552A1
The present disclosure provides salt and/or crystal form for compounds, especially for compounds as casein kinase inhibitors.  
WO/2023/243659A1
Provided is a pharmaceutical composition for treating obsessive-compulsive disorder. The present invention pertains to: (1) a pharmaceutical composition containing a dopamine D1 receptor stimulant as an active ingredient for treating o...  
WO/2023/241390A1
The compositions for preventing or treating insomnia, improving sleep quality, improving skin appearance, reducing halitosis and increasing relaxation towards sleep, improving sleep quality. In particular, the compositions comprise a pro...  
WO/2023/245055A1
The present disclosure relates to dosing regimens and methods for treatment of X-linked adrenoleukodystrophy (X-ALD) using thyroid receptor beta agonists.  
WO/2023/241688A1
The present invention relates to a composition for treating and resisting blood coagulation and use thereof, and particularly relates to a pharmaceutical composition containing (7aS, 2'S)-2-oxo-clopidogrel and use thereof. The present in...  
WO/2023/245185A1
Compositions that include cannabinoids other than tetrahydrocannabinol (THC), such as cannabigerol (CBG) in combination with tetrahydrocannabinol (THC) or formulated to be combined with THC, and methods of preparation and use thereof are...  
WO/2023/245008A1
Provide herein are methods of treating human patients with familial Alzheimer's disease that result in delayed in symptom onset and/or slowed cognitive decline by administering a humanized monoclonal anti-amyloid beta (Aβ) antibody.  
WO/2023/244574A1
Disclosed herein are aldehyde dehydrogenase (ALDH-2) inhibitor compounds, such as a compounds of Formula (I) or Formula (II), pharmaceutical compositions comprising these inhibitor compounds, and uses of these compounds and compositions,...  
WO/2023/244051A1
Provided is a composition for preventing, alleviating or treating neurodegenerative disorders, comprising, as an active ingredient, a Davallia mariesii extract or a fraction thereof, or a compound isolated therefrom.  
WO/2023/242844A1
The present invention provides a therapeutic agent selected from (a) a mitochondria targeted-insulin-like growth factor- 1 receptor (mitoIGFIR) agonist; and (b) a nucleic acid molecule encoding for the expression of mitoIGFIR or a portio...  
WO/2023/241608A1
The present application relates to compounds of formula (I) and formula (1'), which are useful as inhibitors of CSF-1R in the treatment of various diseases.  
WO/2023/243698A1
Problem The purpose of the present invention is to provide a novel method for prevention and/or treatment of opioid tolerance or opioid dependence. Specifically, the purpose of the present invention is to develop peptide-based blockers t...  
WO/2023/242809A1
The present disclosure relates to hydrochloride salts of 4-[(5-chloropyridin-2-yl)methoxy]-1-[3-(propan-2-yl)-1H,2H,3 H,4H,5H-[1,4]diazepino[1,7-a]indol-9-yl]-1,2- dihydropyridin-2-one (Compound 1), a potent, and orally active selective ...  
WO/2023/242296A1
The invention relates to the use of a Phaeodactylum tricornutum extract, alone or in combination with an extract selected from a guarana extract (Paullinia cupana), a ginseng extract (Panax ginseng), a Gingko biloba extract, a Nelumbo nu...  
WO/2023/244685A1
The disclosure provides methods of delaying an aging-related change, increasing lifespan, and reducing risk of, delaying onset of, or treating an aging-related disease in a subject. The methods comprise administering to the subject an ef...  
WO/2023/241551A1
The present disclosure provides salt and/or crystal form for compounds, especially for compounds as casein kinase inhibitors.  
WO/2023/240971A1
A pharmaceutical composition and a brexpiprazole orally dissolving film. The pharmaceutical composition comprises brexpiprazole, a film-forming material, and a plasticizer, wherein D90 of brexpiprazole meets: 25µm≤D90≤50µm. The pha...  
WO/2023/243606A1
The present invention provides a polyionic complex of a nucleic acid and a cationic polymer, wherein the polyionic complex has a positive surface potentiation and is capable of delivering a nucleic acid to brain tissue. The polyionic com...  
WO/2023/244563A1
Disclosed herein are aldehyde dehydrogenase (ALDH-2) inhibitor compounds, such as a compounds of Formula (I) or Formula (II), pharmaceutical compositions comprising these inhibitor compounds, and uses of these compounds and compositions,...  
WO/2023/241717A1
Provided is use of a substance capable of up-regulating ISG gene expression in preparing a drug or reagent for promoting the regeneration and repair capacity of tissues or complex structures or organs of mammals. The substance for up-reg...  
WO/2023/241290A1
The present invention relates to the technical field of anti-tumor and anti-nerve-injury drug synthesis. Disclosed are an anti-tumor and anti-nerve-injury pharmaceutical compound based on a quinolizidine derivative, a use and a preparati...  
WO/2023/244584A1
Disclosed herein are aldehyde dehydrogenase (ALDH-2) inhibitor compounds, such as a compounds of Formula (I) or Formula (II), pharmaceutical compositions comprising these inhibitor compounds, and uses of these compounds and compositions,...  
WO/2023/245107A1
This disclosure provides CBD-loaded or (CBD and nicotine)-loaded microcapsules for use in treating or preventing anorexia, emesis, pain, inflammation, multiple sclerosis, a neurodegenerative disorder, epilepsy, glaucoma, osteoporosis, sc...  
WO/2023/244772A1
The present invention provides methods for treating a neurodegenerative disease in a subject, preventing a neurodegenerative disease in a subject, increasing neurons in a region of the brain of a subject, increasing small ubiquitin-like ...  
WO/2023/244968A1
Described herein are methods of treating autoimmune diseases of the central nervous system and multiple sclerosis with a combination of an HDAC inhibitor and an antiviral drug.  
WO/2023/242355A1
The present invention relates to a compound of formula (I), which is a phosphate ester of apomorphine, or a pharmaceutically acceptable salt thereof. The apomorphine phosphate ester according to the invention exhibits remarkably advantag...  
WO/2023/042178A9
This invention provides compositions and methods for treating or preventing neurodegenerative disorders with combinations of at least two drugs from two or more classes of pharmacological activity. The subject neurodegenerative disorders...  
WO/2023/242576A1
The present invention relates to crystalline forms of the synthetic, non-natural cannabinoid (1'R,2'R)-5'-methyl-4-(1-methyl-1H-pyrazol-4-yl)-2'-(prop-1- en-2-yl)-1',2',3',4'-tetrahydro-[1,1'- biphenyl]-2,6-diol, methods for their produc...  
WO/2023/242285A1
A transmucosal delivery composition in form of a sublingual orally dispersible film comprising cladribine as active ingredient and comprising at least two hydrophilic polymers, wherein the at least two hydrophilic polymers represent at l...  
WO/2023/241669A1
Provided are a CRISPR-Cas effector protein, a gene editing system therefor, and an application. The CRISPR-Cas effector protein comprises a protein which is at least 70% identical to the amino acid sequence of any one of SEQ ID NOs: 1 to...  
WO/2023/244062A1
Provided is an orodispersible powder composition containing donepezil or a pharmaceutically acceptable salt thereof as a main ingredient, the orodispersible powder composition being characterized by comprising: a diluent composed of a su...  
WO/2023/236781A1
A method for preventing or treating mental diseases, alleviating symptoms of mental diseases or delaying the progression of mental diseases, comprising: administering to an individual in need thereof at least two of a prophylactically or...  
WO/2023/240177A1
Disclosed herein are products, methods, and uses for treating, ameliorating, or delaying the progression of, and/or preventing seizures, an epileptic disease or disorder, an intellectual or developmental disability, autism, or an autism ...  
WO/2023/238869A1
The present invention addresses the problem of providing a preventative agent or a therapeutic agent for amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Huntington's disease (HD), spinocerebellar ataxia (SCA), aging-relate...  
WO/2023/236920A1
This disclosure provides compounds of Formula (1), compositions comprising the same, and methods of using the same, including uses in modulating SARM1 and treating various diseases and conditions, e.g., those caused by axonal degeneration.  
WO/2023/237627A1
A modified U7 snRNA construct comprising at least one antisense sequence having between 16 to 30 nucleotides which are at least 90% complementary to a splicing element of a TDP- 43 regulated cryptic exon sequence or flanking regions ther...  
WO/2023/236739A1
The present invention belongs to the field of medicine and health care. Disclosed is use of a nucleotide mixture in the preparation of a formulation for preventing and treating Alzheimer's disease. The nucleotide mixture is composed of f...  
WO/2023/236762A1
Use of high-dose crocin in the preparation of a rapid-acting anti-depressant. The rapid-acting refers to taking effect within one week of continuous administration and further to taking effect within 24 hours of a single administration. ...  
WO/2023/236797A1
Disclosed in the present invention are a hangtaimycin derivative, a preparation method therefor, and the use thereof. The hangtaimycin derivative is prepared by performing fermentation in an SFMR culture medium by using Streptomyces spec...  
WO/2023/240203A1
Disclosed herein are patches, methods, devices, and systems for delivering a non-aggregating peptide, such as alcadein and its fragments, into a subject. In some aspects, the patch includes a backing, a matrix comprising a non-aggregatin...  

Matches 451 - 500 out of 115,935